Brainsway announces publication of post-marketing data analysis for Deep TMS

BrainsWay announced the publication of an expansive post-marketing data analysis demonstrating high response and remission rates for depression and anxious depression patients undergoing Deep Transcranial Magnetic Stimulation treatment. The data, published in Psychiatry Research, showed the substantial benefits of Deep TMS treatment for depression, with patients who had received 30 or more treatments achieving an 82% response rate and a 65% remission rate. In the study, BrainsWay collected an aggregate data set from 1,753 patients across 21 clinics, of which 1,351 patients met the inclusion criteria for the analysis. All patients were treated with the Deep TMS H1 Coil utilizing either a standard protocol or a shorter intermittent theta burst protocol. Outcomes were measured with clinician-based scales and/or patient self-administered questionnaires designed specifically for depression. This analysis showed that the average patient achieved sustained response at 16 sessions, or 21 days after beginning treatment. The evidence also showed that efficacy rates were similar between the standard and iTBS protocols. Data from questionnaires which are not specific to depression, and thus less relevant for assessing depression changes, were intentionally excluded.